NeoGenomics Competitors

Cooper Companies (NYSE:COO) and NeoGenomics (NASDAQ:NEO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Risk & Volatility

Cooper Companies has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, NeoGenomics has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Cooper Companies and NeoGenomics, as reported by MarketBeat.com.

Cooper Companies presently has a consensus target price of $339.9167, indicating a potential downside of 2.54%. NeoGenomics has a consensus target price of $37.1818, indicating a potential downside of 11.75%. Given Cooper Companies' higher possible upside, equities research analysts plainly believe Cooper Companies is more favorable than NeoGenomics.

Valuation and Earnings

This table compares Cooper Companies and NeoGenomics' gross revenue, earnings per share and valuation.

Cooper Companies has higher revenue and earnings than NeoGenomics. Cooper Companies is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cooper Companies and NeoGenomics' net margins, return on equity and return on assets.

Institutional and Insider Ownership

88.8% of Cooper Companies shares are owned by institutional investors. Comparatively, 91.7% of NeoGenomics shares are owned by institutional investors. 1.4% of Cooper Companies shares are owned by company insiders. Comparatively, 6.5% of NeoGenomics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Cooper Companies beats NeoGenomics on 9 of the 15 factors compared between the two stocks.

Teladoc Health (NYSE:TDOC) and NeoGenomics (NASDAQ:NEO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Volatility & Risk

Teladoc Health has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, NeoGenomics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Institutional & Insider Ownership

87.4% of Teladoc Health shares are owned by institutional investors. Comparatively, 91.7% of NeoGenomics shares are owned by institutional investors. 3.4% of Teladoc Health shares are owned by company insiders. Comparatively, 6.5% of NeoGenomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Teladoc Health and NeoGenomics' revenue, earnings per share and valuation.

NeoGenomics has lower revenue, but higher earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Teladoc Health and NeoGenomics, as reported by MarketBeat.

Teladoc Health currently has a consensus target price of $214.5714, suggesting a potential downside of 1.01%. NeoGenomics has a consensus target price of $37.1818, suggesting a potential downside of 11.75%. Given Teladoc Health's higher possible upside, analysts plainly believe Teladoc Health is more favorable than NeoGenomics.

Profitability

This table compares Teladoc Health and NeoGenomics' net margins, return on equity and return on assets.

Summary

NeoGenomics beats Teladoc Health on 10 of the 15 factors compared between the two stocks.

Hologic (NASDAQ:HOLX) and NeoGenomics (NASDAQ:NEO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Hologic and NeoGenomics, as reported by MarketBeat.

Hologic currently has a consensus target price of $67.1538, suggesting a potential upside of 1.98%. NeoGenomics has a consensus target price of $37.1818, suggesting a potential downside of 11.75%. Given Hologic's higher possible upside, analysts plainly believe Hologic is more favorable than NeoGenomics.

Profitability

This table compares Hologic and NeoGenomics' net margins, return on equity and return on assets.

Volatility & Risk

Hologic has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, NeoGenomics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Institutional & Insider Ownership

93.7% of Hologic shares are owned by institutional investors. Comparatively, 91.7% of NeoGenomics shares are owned by institutional investors. 1.0% of Hologic shares are owned by company insiders. Comparatively, 6.5% of NeoGenomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Hologic and NeoGenomics' revenue, earnings per share and valuation.

NeoGenomics has lower revenue, but higher earnings than Hologic. Hologic is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Summary

Hologic beats NeoGenomics on 9 of the 15 factors compared between the two stocks.

NeoGenomics (NASDAQ:NEO) and Teleflex (NYSE:TFX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Analyst Ratings

This is a summary of recent ratings for NeoGenomics and Teleflex, as reported by MarketBeat.com.

NeoGenomics currently has a consensus target price of $37.1818, suggesting a potential downside of 11.75%. Teleflex has a consensus target price of $389.40, suggesting a potential upside of 8.45%. Given Teleflex's higher possible upside, analysts clearly believe Teleflex is more favorable than NeoGenomics.

Profitability

This table compares NeoGenomics and Teleflex's net margins, return on equity and return on assets.

Risk and Volatility

NeoGenomics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Teleflex has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.

Institutional and Insider Ownership

91.7% of NeoGenomics shares are owned by institutional investors. Comparatively, 91.3% of Teleflex shares are owned by institutional investors. 6.5% of NeoGenomics shares are owned by company insiders. Comparatively, 2.2% of Teleflex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares NeoGenomics and Teleflex's revenue, earnings per share and valuation.

Teleflex has higher revenue and earnings than NeoGenomics. Teleflex is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Summary

Teleflex beats NeoGenomics on 9 of the 15 factors compared between the two stocks.

NeoGenomics (NASDAQ:NEO) and Smith & Nephew (NYSE:SNN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Analyst Ratings

This is a summary of recent ratings for NeoGenomics and Smith & Nephew, as reported by MarketBeat.com.

NeoGenomics currently has a consensus target price of $37.1818, suggesting a potential downside of 11.75%. Smith & Nephew has a consensus target price of $42.00, suggesting a potential upside of 10.38%. Given Smith & Nephew's higher possible upside, analysts clearly believe Smith & Nephew is more favorable than NeoGenomics.

Profitability

This table compares NeoGenomics and Smith & Nephew's net margins, return on equity and return on assets.

Risk and Volatility

NeoGenomics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.

Institutional and Insider Ownership

91.7% of NeoGenomics shares are owned by institutional investors. Comparatively, 9.1% of Smith & Nephew shares are owned by institutional investors. 6.5% of NeoGenomics shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares NeoGenomics and Smith & Nephew's revenue, earnings per share and valuation.

Smith & Nephew has higher revenue and earnings than NeoGenomics. Smith & Nephew is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Summary

NeoGenomics beats Smith & Nephew on 9 of the 15 factors compared between the two stocks.

NeoGenomics (NASDAQ:NEO) and Bio-Rad Laboratories (NYSE:BIO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk.

Risk & Volatility

NeoGenomics has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.

Valuation & Earnings

This table compares NeoGenomics and Bio-Rad Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Bio-Rad Laboratories has higher revenue and earnings than NeoGenomics. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for NeoGenomics and Bio-Rad Laboratories, as provided by MarketBeat.

NeoGenomics presently has a consensus price target of $37.1818, suggesting a potential downside of 11.75%. Bio-Rad Laboratories has a consensus price target of $577.75, suggesting a potential upside of 3.27%. Given Bio-Rad Laboratories' higher possible upside, analysts plainly believe Bio-Rad Laboratories is more favorable than NeoGenomics.

Profitability

This table compares NeoGenomics and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Institutional and Insider Ownership

91.7% of NeoGenomics shares are held by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are held by institutional investors. 6.5% of NeoGenomics shares are held by insiders. Comparatively, 27.5% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Bio-Rad Laboratories beats NeoGenomics on 10 of the 15 factors compared between the two stocks.